Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mpox Epidemiology and Risk Factors, Nigeria, 2022.
Ogoina D, Dalhat MM, Denue BA, Okowa M, Chika-Igwenyi NM, Oiwoh SO, Tobin EA, Yusuff HA, Ojimba AO, Christian UC, Aremu JT, Gomerep SS, Habila KL, Awang SK, Adekanmbi O, Iroezindu M, Onukak A, Falodun O, Sunday M, Johnson SM, Olaitan A, Onyeaghala C, Alasia D, Mmerem J, Unigwe U, Kwaghe V, Adeiza MA; Nigerian Infectious Diseases Society (NIDS) mpox study group. Ogoina D, et al. Emerg Infect Dis. 2024 Sep;30(9):1799-1808. doi: 10.3201/eid3009.240135. Epub 2024 Aug 10. Emerg Infect Dis. 2024. PMID: 39127124 Free PMC article.
Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: a cohort study.
Ogoina D, Dalhat MM, Denue BA, Okowa M, Chika-Igwenyi NM, Yusuff HA, Christian UC, Adekanmbi O, Ojimba AO, Aremu JT, Habila KL, Oiwoh SO, Tobin EA, Johnson SM, Olaitan A, Onyeaghala C, Gomerep SS, Alasia D, Onukak AE, Mmerem J, Unigwe U, Falodun O, Kwaghe V, Awang SK, Sunday M, Maduka CJ, Na'uzo AM, Owhin SO, Mohammed AA, Adeiza MA; Nigerian Infectious Diseases Society Mpox Study Group. Ogoina D, et al. Among authors: owhin so. Lancet Infect Dis. 2023 Dec;23(12):1418-1428. doi: 10.1016/S1473-3099(23)00427-9. Epub 2023 Aug 22. Lancet Infect Dis. 2023. PMID: 37625431
A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever.
Olayinka AT, Bourner J, Akpede GO, Okoeguale J, Abejegah C, Ajayi NA, Akude C, Ayodeji O, Bausch DG, de Clerck H, Dan-Nwafor C, Dunning J, Erameh C, Eze JN, Formenty P, Gillesen A, Jalloh S, Jaspard M, Jegede T, Maikere J, Malvy D, Ogbaini-Emovon E, Ojo OE, Okogbenin S, O'Neill K, Orji ML, Owhin SO, Ramharter M, Samuels RJ, Shehu N, Merson L, Salam AP, Kayem ND, Horby P, Ihekweazu C, Olliaro P. Olayinka AT, et al. Among authors: owhin so. PLoS Negl Trop Dis. 2022 Jan 6;16(1):e0010089. doi: 10.1371/journal.pntd.0010089. eCollection 2022 Jan. PLoS Negl Trop Dis. 2022. PMID: 34990453 Free PMC article.
Association of hypoalbuminemia and reversal of albumin-to-globulin ratio with morbidity outcome among hospitalized Lassa fever infected patients at a dedicated treatment center in Ondo state, south-western Nigeria.
Owhin SO, Abejegah C, Fasipe OJ, Oke C, Abidoye A, Osagbaekhoe A, Awe A, Etafo I, Iredia E, Ayodeji O, Olatunde L, Ojo O, Alabi J, Akhideno PE, Ejiyere H, Stephen Adeke A, Azegbeobor J, Ahmed L. Owhin SO, et al. Future Sci OA. 2020 Aug 13;6(10):FSO620. doi: 10.2144/fsoa-2020-0075. Future Sci OA. 2020. PMID: 33312698 Free PMC article.